Itch and autophagy-mediated NF-κB activation contributes to inhibition of cathepsin D-induced sensitizing effect on anticancer drugs

Seung Un Seo1,4, Seon Min Woo1,4, Kyoung-jin Min2,5 and Taeg Kyu Kwon1,3✉

© The Author(s) 2022

Inhibition of cathepsin D (Cat D) sensitizes cancer cells to anticancer drugs via RNF183-mediated downregulation of Bcl-xL expression. Although NF-κB activation is involved in the upregulation of RNF183 expression, the molecular mechanism of NF-κB activation by Cat D inhibition is unknown. We conducted this study to investigate the molecular mechanism underlying Cat D-mediated NF-κB activation. Interestingly, Cat D inhibition-induced IκB degradation in an autophagy-dependent manner. Knockdown of autophagy-related genes (ATG7 and Beclin1) and lysosome inhibitors (chloroquine and bafilomycin A1) blocked IκB degradation via Cat D inhibition. Itch induced K63-linked ubiquitination of IκB and then modulated the protein stability of IκB by Cat D inhibition. Inhibition of Cat D-mediated Itch activation was modulated by the JNK signaling pathway, and phosphorylated Itch could bind to IκB, resulting in polyubiquitination of IκB. Additionally, inhibition of Cat D increased autophagy flux via activation of the LKB1-AMPK-ULK1 pathway. Therefore, our results suggested that Cat D inhibition activated NF-κB signaling via degradation of autophagy-dependent IκB, which is associated with the upregulation of RNF183, an E3 ligase of Bcl-xL. Cat D inhibition enhances TRAIL-induced apoptosis through Bcl-xL degradation via upregulation of RNF183.

Cell Death and Disease (2022)13:552; https://doi.org/10.1038/s41419-022-05011-4

INTRODUCTION

Cathepsin D (Cat D) is highly expressed in several cancers [1–7], and it is involved in tumor-promoting effects, such as an increased invasion/migration [8–10] and resistance to anticancer drugs [11]. Inhibition of Cat D induces H2O2-induced apoptosis in HeLa cells [12] and sensitizes neuroblastoma cells to doxorubicin [11]. Particularly, the pro-tumoral effects of Cat D are well known in breast cancer. Cat D is a marker for poor prognosis in breast cancer [13, 14], and Cat D deficiency in the mammary epithelium transiently delays breast cancer progression by inhibiting mTORC1 signaling [15]. Cat D inhibition sensitizes cancer cells to anticancer drugs via RNF183-mediated Bcl-xL degradation [16]. The upregulation of RNF183, which is a key E3 ligase for Bcl-xL degradation, is mainly regulated by activation of the NF-κB signaling pathway [16]. However, the molecular mechanisms underlying NF-κB activation with Cat D inhibition remain unclear.

NF-κB is an important transcription factor involved in multiple cellular functions [13–17]. In the resting state, the IκB-NF-κB complex exists in an inactive form in the cytoplasm. Several stimuli, such as inflammatory cytokines, induce IκB phosphorylation, resulting in the degradation of IκB [17]. The released NF-κB translocates from the cytosol to the nucleus, binds to the target gene promoter, and regulates gene expression. Therefore, degradation of IκB is essential for the activation of NF-κB signaling, and it is mainly mediated via the ubiquitin-proteasome pathway [18]. Moreover, β-TrCP is a major E3 ligase for IκB degradation [19–21]. When IκB is phosphorylated at S32 and S36 through stimuli, β-TrCP induces K48-linked polyubiquitination at K21 and K22 [22].

In this study, we investigated the molecular mechanism of IκB degradation through Cat D inhibition and identified a novel mechanism of autophagy-lysosome-dependent IκB degradation. NF-κB activation contributed to the upregulation of RNF183, and RNF183-mediated destabilization of Bcl-xL played a critical role in the sensitizing effect of Cat D on anticancer drugs.

MATERIALS AND METHODS

Cell culture and materials

Human cancer cell lines Caki, HT29, DU145 and A549 were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (Welgene, Gyeongsan, Korea), 1% penicillin–streptomycin, and 100 μg/mL gentamycin (Thermo Fisher Scientific, Waltham, MA, USA). Details of the reagents, antibodies, siRNAs, and plasmids used are provided in Supplementary Table 1.

Generation of Cat D knockout (KO) cells

Two CRISPR sgRNAs, oligomer1, 5-CAC CGA TGG GCC CCT CGG TCA CGG C-3 and oligomer2, 5-AAA CGC CGT GAC CGA GGG GCC GAT C-3, were designed...
using CRISPR. The cell lines were established by transfecting sgRNAs into Caki cells using the Lipofectamine™ 2000 reagent (AptaBio, Yongin, Korea). Cells were selected on 0.5 μg/mL puromycin, and Cat D KO efficiency was analyzed using western blot analysis.

**Western blot analysis**

Cells were collected and lysed in RIPA lysis buffer, and the lysates were centrifuged at 13,000 × g and 4 °C for 15 min [23]. The supernatants were collected and boiled in 5× sample buffer at 95 °C for 5 min. Proteins were separated using SDS-PAGE and transferred onto nitrocellulose membranes (GE Healthcare Life Sciences, Pittsburgh, PA, USA). The protein bands were detected using an enhanced chemiluminescence reagent kit (EMD Millipore, Darmstadt, Germany).

**Ubiquitination assay**

Ubiquitination assay was performed as previously described [24]. Cells were co-transfected with an HA-tagged ubiquitin (HA-Ub) plasmid, and they were treated with MG132 for 12 h. Immunoprecipitation was performed using anti-ubiquitin, and ubiquitination of endogenous IκBα was assessed using an HRP-conjugated anti-ubiquitin antibody under denaturing conditions.

**Immunoprecipitation assay**

Cells were collected, washed with PBS, lysed with RIPA lysis buffer containing 10 mM N-ethylmaleimide (EMD Millipore) and 1 mM PMSF, and sonicated on ice for protein extraction. After sonication, the cell lysates were centrifuged at 13,000 × g and 4 °C for 15 min. The supernatants were then incubated with 20 μL of Protein G agarose beads by mixing on a rotator at 4 °C for 2 h. Cell lysates were washed with RIPA lysis buffer containing 10 mM N-ethylmaleimide and 1 mM PMSF (Sigma-Aldrich, St. Louis, MO, USA), and they were boiled in 2× sample buffer for 10 min. The protein–protein interactions were verified via western blot analysis.

**Transfection and luciferase assay**

The cells were transfected with siRNA using Lipofectamine RNAiMAX (Thermo Fisher Scientific), and they were transiently transfected with the promoter plasmid using Lipofectamine™ 2000 (Thermo Fisher Scientific). After treatment, the cells were collected and lysed in a lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM EDTA, 10% glycerol, and Triton X-100). The apoptotic population was assessed using a BD Accuri™ C6 cytometer (BD Biosciences, San Jose, CA, USA).

**RESULTS**

**Inhibition of Cat D activates the NF-κB signaling pathway via autophagy-dependent IκB degradation**

Inhibition of Cat D sensitizes cancer cells to anticancer drugs via downregulation of Bcl-xL while upregulation of RNF183 plays a critical role in Bcl-xL degradation [16]. Since inhibition of Cat D increased RNF183 mRNA expression by activating the NF-κB signaling pathway, we examined how inhibition of Cat D activates NF-κB signaling. As shown in Fig. 1A, B, Cat D knockdown or knockout (KD or KO) increased the phosphorylation of p65 and degradation of IκBα in all tested cancer cell lines. Moreover, the catalytically inactive mutants of Cat D, D97N and D97E, increased RNF183 mRNA expression by activating the NF-κB signaling pathway via autophagy-lysosome-dependent degradation. Lysosome functional inhibitors chloroquine and bafilomycin A1 significantly reversed IκBα degradation in Cat D KD cells (Fig. 1D). Furthermore, KD of autophagy-related genes Beclin 1 and ATG7 blocked the tumor necrosis factor-α (TNF-α)-induced degradation of IκBα (Fig. 1D). Therefore, we investigated whether the autophagy-lysosome pathway, another important proteolytic pathway, is involved in IκBα degradation. Lysosome functional inhibitors chloroquine and bafilomycin A1 significantly reversed IκBα degradation in Cat D KD cells (Fig. 1D). Furthermore, KD of autophagy-related genes Beclin 1 and ATG7 blocked the tumor necrosis factor-α (TNF-α)-induced degradation of IκBα. Therefore, we investigated whether the autophagy-lysosome pathway, another important proteolytic pathway, is involved in IκBα degradation. Lysosome functional inhibitors chloroquine and bafilomycin A1 significantly reversed IκBα degradation in Cat D KD cells (Fig. 1D). Furthermore, KD of autophagy-related genes Beclin 1 and ATG7 blocked the tumor necrosis factor-α (TNF-α)-induced degradation of IκBα (Fig. 1D). Therefore, we investigated whether the autophagy-lysosome pathway, another important proteolytic pathway, is involved in IκBα degradation. Lysosome functional inhibitors chloroquine and bafilomycin A1 significantly reversed IκBα degradation in Cat D KD cells (Fig. 1D). Furthermore, KD of autophagy-related genes Beclin 1 and ATG7 blocked the tumor necrosis factor-α (TNF-α)-induced degradation of IκBα (Fig. 1D). Therefore, we investigated whether the autophagy-lysosome pathway, another important proteolytic pathway, is involved in IκBα degradation. Lysosome functional inhibitors chloroquine and bafilomycin A1 significantly reversed IκBα degradation in Cat D KD cells (Fig. 1D). Furthermore, KD of autophagy-related genes Beclin 1 and ATG7 blocked the tumor necrosis factor-α (TNF-α)-induced degradation of IκBα. Therefore, we investigated whether the autophagy-lysosome pathway, another important proteolytic pathway, is involved in IκBα degradation. Lysosome functional inhibitors chloroquine and bafilomycin A1 significantly reversed IκBα degradation in Cat D KD cells (Fig. 1D). Furthermore, KD of autophagy-related genes Beclin 1 and ATG7 blocked the tumor necrosis factor-α (TNF-α)-induced degradation of IκBα.
(Fig. 1F), we investigated whether ubiquitination of IκB is induced by Itch E3 ligase, an E3 ligase that induces the formation of a K63-linked ubiquitin chain [27]. Itch KD or pharmacologic inhibitor (clomipramine) completely blocked IκB degradation and/or p65 phosphorylation following Pep A treatment (Fig. 2A, B). To confirm IκB degradation by Itch E3 ligase, we identified the interaction between Itch and IκB. Cat D inhibition increased IκB-Itch binding while TNF-α induced IκB-B-TrCP binding (Fig. 2C). Further, an increase in the K63-linked ubiquitin chain of IκB via Cat D inhibition was blocked by Itch KD (Fig. 2D). When de novo protein synthesis was blocked by cycloheximide treatment, overexpression of Itch dramatically decreased IκB protein stability; however, the catalytically inactive mutant Itch (C832G) inhibited IκB degradation in Pep A-treated cells (Fig. 2E). In contrast, KD of Itch increased IκB protein stability following Pep A treatment as compared to that of control siRNA (Fig. 2F). These data suggested that Itch is a critical E3 ligase that modulates Cat D inhibition-mediated IκB stability.

**Fig. 1** Inhibition of cathepsin D (Cat D) induces IκB degradation via the autophagy-lysosome pathway. A, B Examination of protein expression in Caki/Cat D WT and KO cells (A) or Cont and Cat D siRNA-transfected cells (B). C Caki/Cat D KO cells and Cat D siRNA-transfected cells were transfected with vector, Cat D WT, or Cat D mutants (D97N and D295N), and protein expression was determined. D Caki cells were transiently transfected with Cont siRNA or Cat D siRNA, and they were treated with 0.5 μM MG132, 2.5 μM lactacystin, 10 μM chloroquine, and 5 nM bafilomycin A1 for 24 h (left panel). Caki cells were treated with 0.5 μM MG132 for 30 min, and 20 ng/mL TNF-α was then added for 24 h (right panel). E Cancer cells (Caki, HT29 and DU145) were transiently transfected with Cont siRNA, Beclin1 siRNA, and ATG7 siRNA, and they were further treated with 2 μM Pep A for 24 h. F Caki cells were transiently transfected with HA-Ub, HA-K48-Ub, and HA-K63-Ub, and they were pretreated with 0.5 μM MG132 and 5 nM bafilomycin A1. Thereafter, they were treated with 2 μM Pep A or 20 ng/mL TNF-α for 24 h. The ubiquitination of endogenous IκB was analyzed via the DUB assay. Protein expression was measured via western blotting (A–F).
Inhibition of Cat D increases activation of Itch via JNK-mediated phosphorylation of Itch at T222

It has been reported that activation of Itch is regulated by JNK-dependent phosphorylation [28]. Therefore, we investigated whether inhibition of Cat D modulates phosphorylation of Itch. As shown in Fig. 3A and B, the extent of Itch phosphorylation at T222 significantly increased following Pep A treatment, which gradually enhanced JNK phosphorylation in all tested cancer cell lines. Furthermore, phosphorylation of Itch and degradation of IκB were completely blocked by a JNK-specific inhibitor (SP600125), and overexpression of kinase-inactive mutant JNK (JNK mutant) diminished Itch phosphorylation and IκB degradation by Cat D KD (Fig. 3C, D). Phosphorylation of Itch induced conformational changes related to E3 ligase activity. Therefore, we investigated whether phosphorylation of Itch plays a critical role in Itch-IκB binding. The JNK inhibitor diminished the interaction between Itch and IκB via inhibition of Itch phosphorylation (Fig. 3E). Therefore, our data suggested that JNK activation through Cat D inhibition plays a critical role in IκB degradation via phosphorylation of Itch at T222.

Inhibition of Cat D increases autophagy flux

IκB degradation was mediated by the autophagy-lysosome-dependent pathway (Fig. 1D, E). Therefore, to evaluate the role of Cat D in autophagic flux [29], lipidated LC3 (LC3 II) in Cat D KO/KD cells was examined. LC3 II levels were higher in Cat D KO/ KD cells than those in control cells (Fig. 4A). Furthermore, to confirm this, cells were transfected with the mRFP-GFP-LC3 plasmid construct, which measures autophagic flux [30, 31]. Since the fusion of autophagosomes with lysosomes resulted in quenching of the GFP signal, autophagosomes (GFP−/RFP−) and autolysosomes (GFP+/RFP+) can be distinguished by the ratio of GFP and RFP signals. Pep A increased the number of autolysosomes (GFP+/RFP+) and lysosome inhibitors increased the levels of LC3 II (Fig. 4B). To further confirm this, cells were transfected with the mRFP-GFP-LC3 plasmid construct, which measures autophagic flux [30, 31]. Since the fusion of autophagosomes with lysosomes resulted in quenching of the GFP signal, autophagosomes (GFP−/RFP−) and autolysosomes (GFP+/RFP+) can be distinguished by the ratio of GFP and RFP signals. Pep A increased the number of autophagosomes (GFP+/RFP+) and lysosome inhibitor baflomycin A1 increased the number of autophagosomes (GFP+/RFP+) following Pep A treatment (Fig. 4C). Therefore, our data suggested that inhibition of Cat D increases autophagic flux.

LKB1-AMPK-ULK1 signal axis is involved in an increase of autophagy flux via Cat D inhibition

Next, we examined how Cat D inhibition increases autophagic flux. ULK1 kinase is an initiating autophagy-related kinase, and the regulation of ULK1 phosphorylation plays a central role in...
autophagy. AMPK increases the phosphorylation of S317/S777, which is essential for ULK1 activation, and mTOR prevents ULK1 activation via phosphorylation of S757 [33]. Therefore, we investigated whether inhibition of Cat D modulates ULK1 activation. Cat D KO/KD decreased the phosphorylation of ULK1 at S757 and increased the phosphorylation of ULK1 at S777 in all tested cancer cell lines (Fig. 5A). In line with these results, Cat D KO/KD inhibited mTOR phosphorylation and induced AMPK phosphorylation (Fig. 5B). To confirm the involvement of mTOR dephosphorylation in Pep A-induced NF-κB activation, we used the mTOR specific inhibitor (everolimus). Everolimus more increased p65 phosphorylation and IκB degradation (Fig. 5C).
As AMPK suppresses mTOR signaling, we examined the effect of AMPK signaling inhibition on autophagy. AMPK KD decreased LC3 II formation via ULK1 inhibition and mTOR dephosphorylation in Pep A-treated cells (Fig. 5D). Further, the AMPK inhibitor Compound C and AMPK KD also blocked LC3 II formation and IκB degradation (Fig. 5E, F). These results indicated that Cat D inhibition increases autophagy flux via AMPK-dependent modulation of ULK1 phosphorylation.

Three upstream kinases LKB1, CaMKKβ, and TAK1 modulate AMPK activation [34, 35]. Therefore, we investigated the kinases that are involved in Cat D inhibition-mediated iκB degradation through modulation of autophagy flux. As shown in Fig. 5G, LKB1 KD only blocked the degradation of iκB by inhibiting dephosphorylation of ULK1 at S757 and LC3 lipidation in Pep A-treated cells. Neither TAK1 nor CaMKKβ altered iκB degradation following Pep A treatment. Additionally, the LKB1-deficient cell line A549 was resistant to Pep A-treated IκB degradation (Fig. 5H). These results indicated that the LKB1-AMPK-ULK1 signaling pathway plays a critical role in iκB degradation through Cat D inhibition via the modulation of autophagy.

### Autophagy-dependent degradation of iκB increases RNF183 E3 ligase expression

Previously, we reported that inhibition of Cat D sensitized cancer cells to anticancer drugs through RNF183-mediated Bcl-xL degradation [16], and activation of NF-κB signaling is important for the induction of RNF183 expression. Therefore, we investigated whether the upstream signaling of iκB degradation is involved in the modulation of RNF183 expression. KD of autophagy-related genes Beclin1 and ATG7 significantly blocked Pep A-induced RNF183 upregulation and Bcl-xL downregulation (Fig. 6A). Additionally, the catalytically inactive mutant JNK and LKB1 KD blocked Pep A-mediated RNF183 upregulation and Bcl-xL downregulation (Fig. 6B, C). Next, we confirmed whether the regulatory mechanism of RNF183 expression controls sensitivity to anticancer drugs. KD of the autophagy-related genes Beclin1 and ATG7, LKB1, and Itch significantly inhibited the combined treatment of Pep A plus TRAIL-induced apoptosis, PARP cleavage, and Bcl-xL downregulation (Fig. 6D–F). Next, we detected similar results using...
lysates from the in vivo xenograft models (Fig. 6G). Therefore, our results suggested that Cat D inhibition activates the NF-κB signaling pathway, which is related to anticancer activity, via autophagy-dependent IκB degradation.

Cat D indicates inverse correlation with levels of phospho-Itch and LKB1 in human renal clear carcinoma (RCC) tissues

We investigated protein level of phospho-Itch and LKB1 in human renal clear carcinoma (RCC) tissues. When Cat D (82.5%, 33/40) is highly expressed in RCC tumor tissues, phospho-Itch (92.5%, 37/40) and LKB1 (85%, 34/40) were downregulated (Fig. 7A, B). In addition, we found that phospho-Itch and LKB1 has inverse correlation with levels of Cat D expression in RCC (Fig. 7C).

DISCUSSION

In this study, we demonstrated the molecular mechanism of NF-κB activation via Cat D inhibition. Inhibition of Cat D significantly increased IκB degradation in an autophagy-lysosome-dependent manner. Further, inhibition of Cat D increased K63-linked ubiquitination of IκB by Itch E3 ligase. LKB1-AMPK-ULK1 signal axis-mediated autophagy activation is involved in IκB degradation. Autophagy-dependent IκB degradation-mediated NF-κB activation increased RNF183 expression, which was associated with Cat D inhibition-induced Bcl-xl downregulation (Fig. 8).

Itch is a HECT-type E3 ligase containing a C2 domain, four WW motifs, and a HECT domain [36]. Itch was present in the central region with WW whereas PRR combined with C-terminal HECT and its activity was suppressed. When phosphorylated to the PRR motif under certain conditions, the HECT domain was exposed, since the intracellular interaction weakens through conformational changes. It is known that the catalytic activity of HECT domain increases significantly [28]. Phosphorylation of Itch is regulated by JNK. JNK phosphorylates S199, T222, and S232 residues in the PRR motif to regulate Itch activity. In our study, inhibition of Cat D significantly increased JNK phosphorylation (Fig. 3B), and a JNK inhibitor SP600125 completely blocked Itch T222 phosphorylation (Fig. 3C). Inhibition of Itch phosphorylation also reduced the binding of IκB to Itch (Fig. 3E). Although inhibition of Cat D markedly increased JNK phosphorylation, the upstream kinase of JNK in our system was unclear. Reactive oxygen species (ROS) are candidates for activation of JNK signaling. However, since Cat D inhibition did not increase ROS production [16], we ruled out the possibility of ROS being upstream of JNK. Additionally, we found that AMPK KD did not alter JNK phosphorylation by inhibiting Cat D (Fig. 5D). Further investigations are required to clearly identify the upstream kinases involved in Cat D inhibition-mediated JNK activation.

ULK1 activation is associated with autophagy initiation in mammalian cells.ULK1 forms a complex with autophagy-related protein 13 (ATG13), focal adhesion kinase family interacting protein of 200 kDa (FIP200), and ATG101, and its kinase activity is essential for autophagy initiation through phosphorylation of ULK1, ATG13, FIP200, and ATG101 [37–40]. ULK1 activation is modulated by phosphorylation, and mTOR and AMPK mainly phosphorylate ULK1. Phosphorylation regulation by the two kinases plays an important role in determining the protein bound to ULK1. For example, phosphorylation of ULK1 at S757 prevents AMPK interaction, and AMPK-mediated mTOR inactivation...
**Fig. 7** The inverse correlation between Cat D and phospho-Itch or LKB1 expression in renal tumor tissues. A, B Analysis of protein expression in 40 paired primary renal clear carcinoma tissues as compared with the adjacent normal tissues. C The inverse correlation between Cat D and phospho-Itch or LKB1 was observed at the protein levels.

**Fig. 8** Scheme indicating the mechanism of Cat D inhibition-induced sensitizing effect on anticancer drugs via activation of NF-κB signaling. Two molecular mechanisms are associated with autophagy-mediated IκB degradation by Cat D inhibition. First, depletion of Cat D phosphorylates Itch at T222 through activation of JNK signaling. Second, LKB1-mediated AMPK activation by Cat D inhibition phosphorylates ULK1 at S777, while ULK1 at S757 is dephosphorylated by inhibition of mTOR signaling. Subsequently, autophagy-dependent IκB degradation is involved in Cat D inhibition-mediated sensitizing effect to anticancer drugs through RNF183-dependent Bcl-xL downregulation.
decreases the phosphorylation ofULK1 at S757, resulting in interaction withAMPK and phosphorylation ofULK1 at S317 and S777 [33]. In our study, inhibition ofCat D increased the phosphorylation ofULK1 at S777 whereas phosphorylation at S757 was suppressed (Fig. 5A). It was confirmed that phosphorylation ofULK1 due to Cat D inhibition was blocked by AMPK KD, and dephosphorylation ofmTOR was also inhibited by AMPK KD (Fig. 5D). Therefore, AMPK activation via Cat D inhibition plays a key role in autophagy induction. We also identified an upstream kinase ofAMPK. There are three known upstream kinases ofAMPK, LKB1, TAK1, and CaMKKβ. Among them, it is known that LKB1 acts as an upstream kinase ofAMPK as the phenomena that occurred via Cat D inhibition disappeared only when LKB1 was knocked out (Fig. 5G). LKB1 is a serine/threonine kinase known to be a tumor suppressor gene. Mutations in LKB1 have been found in sporadic cancers and Peutz-Jeghers syndrome [41]. By contrast, LKB1 has oncogenic functions. For example, LKB1-deficient cells promote NADPH depletion and increase H₂O₂ production, resulting in the induction of cell death [42], and the loss of LKB1 makes the cells resistant to oncogene-induced transformation [43]. Our findings also confirmed that sensitivity to anticancer drugs increased in the absence ofLKB1 via downregulation ofBcl-xl, indicating that at least the activity ofLKB1 must be suppressed to increase cancer cell death (Fig. 6E). LKB1 activation is regulated by the formation of a heterotrimeric complex with STE20-related kinase adaptor (STRAD) and mouse protein 25 (MO25), both of which maintain the activated conformation ofLKB1 [44]. One of the mechanisms known to regulate the activity ofLKB1 is ubiquitination by Skp2-SCF ligase. K63-linked ubiquitination ofLKB1 increased the integrity ofLKB1-STRAD-MO25 complex [45], and SUMOylation ofLKB1 at K178 also regulates its activity via modulation ofLKB1-AMPK interaction [46] and localization [47]. LKB1 KD dramatically inhibited Pep A-induced RNF183 upregulation and Bcl-xl downregulation (Fig. 6C). Furthermore, LKB1 KD significantly inhibited the combined treatment ofPep A and TRAIL-induced apoptosis (Fig. 6E). Therefore, the LKB1-AMPK-ULK1 axis is a key signaling pathway in Cat D inhibition-induced RNF183 upregulation. However, further studies are needed to determine how Cat D inhibition regulates the activity ofLKB1.

In previous study, we reported that inhibition ofCat D sensitizes cancer cells to anticancer drugs via RNF183-mediated downregulation ofBcl-xl expression [16]. Here, we identified the mechanism ofRNF183 upregulation by Cat D inhibition, and phosphorylation ofItch and activation ofLKB1 have critical roles in upregulation ofRNF183. We also found that Cat D had positive correlation withBcl-xl expression and had inverse correlation with RNF183, p-Itch at T222 and LKB1 (Fig. 7) [16]. Since the expression level ofCat D is correlated with the expression ofanti-apoptotic Bcl-xl, it means that it can exhibit resistance to anticancer drugs. Chemotherapy resistance ofneuroblastomas with amplified MYCN was related with Cat D expression, and they suggest that enhancement ofBcl-2 anti-apoptotic function [11]. In addition, Cat D deficiency in the mammary epithelium delayed breast cancer progression and induced quiescent state by inhibiting mTORC1 signaling [15]. Inhibition ofCat D markedly increased apoptosis by sub-lethal dosage of sorafenib and sunitinib or paclitaxel in Caki and prostate carcinoma DU145 cells (Supplementary Fig. S2). Sorafenib and sunitinib are approved for renal or prostate cell cancer treatment, respectively. Therefore, therapeutic strategies targeting Cat D may increase the sensitivity ofanticancer drugs.

In conclusion, we clearly showed that Cat D inhibition activated NF-kB signaling via IkB degradation by induction ofK63-linked ubiquitination ofIκB using Itch E3 ligase and autophagy flux using LKB1-AMPK-ULK1 activation. Based on our findings, we suggest that inhibition ofCat D can be a target mechanism for controlling sensitivity to anticancer drugs through these novel mechanisms.

REFERENCES

1. Dubey V, Luigan S. Cathepsin D as a promising target for the discovery of novel anticancer agents. Curr Cancer Drug Targets. 2017;17:402.
2. Rochefort H, Capony F, Garcia M. Cathepsin D in breast cancer: From molecular and cellular biology to clinical applications. Cancer Cells. 1990;2:233–8.
3. Zhang M, Wu JS, Yang X, Peng X, Li L, Wang SS, et al. Overexpression Cathepsin D contributes to perineural invasion of salivary adenoid cystic carcinoma. Front Oncol. 2018;8:492.
4. Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: Proliferation, angiogenesis and apoptosis. Oncogene. 2002;21:5951–5.
5. Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guix S, et al. Immunotherapeutic targeting of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7:29.
6. Yang L, Cui M, Zhang L, Song L. FOXM1 facilitates gastric cancer cell migration and invasion by inducing Cathepsin D. Oncotarget. 2017;8:68180–90.
7. Gemoll T, Epping F, Heinrich L, Fritzsche B, Roblick UJ, Szymczak S, et al. Increased cathepsin D protein expression is a biomarker for osteosarcomas, pulmonary metastases and other bone malignancies. Oncotarget. 2015;6:16517–26.
8. Zhang C, Zhang M, Song S. Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation. Cancer Lett. 2018;438:105–15.
9. Park YJ, Kim EK, Bae JY, Moon S, Kim J. Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1. Cancer Lett. 2016;370:222–31.
10. Johnson MD, Torri JA, Lippman ME, Dickson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res. 1993;53:873–7.
11. Sagulenko V, Muth D, Sagulenko E, Paffhausen T, Schwab M, Westermann F. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. Carcinogenesis. 2008;29:1860–77.
12. Han YS, Noh HS, Ha JH, Ahn JS, Hahm JR, Cho HY, et al. Cathepsin D inhibits oxidative stress-induced cell death via activation of autophagy in cancer cells. Cancer Lett. 2012;323:208–14.
13. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990;322:297–302.
14. Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat. 1993;24:219–26.
15. Ketterer S, Mitschke J, Ketscher A, Schlimpert M, Reichardt W, Baueurle N, et al. Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling. Nat Commun. 2020;11:5133.
16. Seo SJ, Woo SM, Im SS, Sang Y, Han E, Kim SH, et al. Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization ofBcl-xl in cancer cells. Cell Death Dis. 2022;13:115.
17. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baueurle PA. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature. 1993;363:244–25.
18. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773–85.
19. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, et al. Identification of the receptor component of the IkappaBAlphabiubiquitin ligase. Nature. 1998;396:590–4.
20. Spencer E, Jiang J, Chen ZJ. Signal-induced ubiquitination of IkappaBAlpha by the F-box protein Slinba-Trip. Genes Dev. 1999;13:284–94.
21. Kanarek N, Ben-Neriah Y. Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol Rev. 2012;246:77–94.
22. Okhate F, Saeki Y, Ishido S, Kanno J, Tanaka K. The K48-K63 Branched Ubiquitin Chain Regulates NF-kappaB Signaling. Mol Cell. 2016;64:251–66.
23. Min KJ, Shahriyar SA, Kwon TK, Arylquin 1, a potent Par-4 secretagogue, induces lysosomal membrane permeabilization-mediated anti-apoptotic cell death in cancer cells. Toxicol Res. 2020;36:167–73.
24. Seo SJ, Woo SM, Kim MW, Lee HS, Kim SH, Kang SC, et al. Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization. Redox Biol. 2020;30:101422.
25. Woo SM, Min KJ, Seo BR, Nam JO, Choi KS, Yoo YH, et al. Cathepsin K overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation ofMcl-1 expression and upregulation ofBim expression. Cell Death Dis. 2014;5:e1514.
26. Olzmann JA, Chin L-S. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy. 2008;4:85–7.

27. Grice GL, Nathan JA. The recognition of ubiquitinated proteins by the proteasome. Cell Mol Life Sci. CMLS. 2016;73:3497–506.

28. Gallagher E, Gao M, Liu Y-C & Karin M. Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci USA. 2006;103:1717–22.

29. Klionsky DJ, Abdelmohsen K, Abe A, Aebischer H, Rice S, Aronson S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222.

30. Kakeya Y, Mizushima N, Ueno T, Yamamoto A, Kisuako T, Noda T, et al. LC3, a mammalian homologue of yeast Atg8p, is localized in autophagosome membrane fractions after processing. EMBO J. 2000;19:5920–8.

31. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452–60.

32. Martina JA, Dab H, Lishu L, Jeong AL, Patange S, Raben N, et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal. 2014;7:ra9.

33. Kim J, Kondou M, Violett B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41.

34. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Idd L, Makela TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol Chem. 2003;278:22288–305.

35. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 2003;13:2004–8.

36. Liu YC. Ubiquitin ligases and the immune response. Annu Rev Immunol. 2004;22:81–127.

37. Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell. 2015;59:285–97.

38. Gallesy E, Filippi BM, Deak M, Allesi DR, van Aalten DM. Structure of the LKB1–STRAD–MO25 complex reveals an allosteric mechanism of kinase activation. Science. 2009;326:1707–11.

39. Lee SW, Li CF, Jin G, Cai Z, Han F, Chan CH, et al. Skp2-dependent ubiquitination and activation of LKB1 for cancer cell survival under energy stress. Mol Cell. 2015;57:1022–33.

40. Dentener MA, Greve JW, Maessen JG, Buurman WA. Role of tumour necrosis factor-alpha in the enhanced sensitivity of mice to endotoxin after exposure to lead. Immunopharmacol Immunotoxicol. 1989;11:321–34.